(AOF) – OPM (Oncodesign Precision Medicine) announces the conclusion of a financing agreement for an amount of 6 million euros granted by three regional banks: Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole Champagne Bourgogne and Société Générale . The company specializing in precision medicine for the treatment of resistant and metastatic cancers specifies that this “non-dilutive” financing is guaranteed by Bpifrance and brings OPM’s cash flow to 13.35 million euros as of 03/10/2023
“This financing allows us to calmly continue the development of OPM-101 towards phase II without losing time due to the prevailing stock market sluggishness,” declares CEO Philippe Genne. “We appreciate this mark of trust emanating from our regional ecosystem which demonstrates its support and strong conviction in OPM’s value creation project.”
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices